AstraZeneca Spikes on Brilinta Approval Rumor, Continues to Rise Following FDA Confirmation

AstraZeneca AZN spiked 1% this afternoon following rumors that Brilinta has received FDA approval. Benzinga then spoke with AstraZeneca, which said it had not yet received approval, but expected to soon. Moments later, the company announced that the FDA had now approved its anti-clotting drug. AstraZeneca has continued to rise in aftermarket trading. At press time, the stock was up more than 3%.